Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 8, 2009, Pages 751-760

  Chen, Cheng Yu ^a,b   Yang, Kuang Yao ^a,c   Chen, Mei Yu ^a   Chen, Hsuan Yu ^d   Lin, Ming Tzer ^e   Lee, Yu Chin ^c   Perng, Reury Perng ^c   Hsieh, Shie Liang ^a,c   Yang, Pan Chyr ^f   Chou, Teh Ying ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Taoyuan Veterans Hospital   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acute lung injury; Biomarker; Prognosis

Indexed keywords

DECOY RECEPTOR 3; INTERLEUKIN 6; STEROID; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; APACHE; ARTICLE; ASSISTED VENTILATION; BLOOD CLOTTING DISORDER; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SURVIVAL RATE; SURVIVAL TIME; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; APACHE; BIOLOGICAL MARKERS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RESPIRATORY DISTRESS SYNDROME, ADULT; ROC CURVE; SEPSIS;

EID: 70349857793     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200902-0222OC     Document Type: Article

References (48)

1. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007;369:1553-1564. (Pubitemid 46670280)
2. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM, Scales DC, Stather DR, Li A, Jones A, et al. Has mortality from acute respiratory distress syndrome decreased over time?: a systematic review. Am J Respir Crit Care Med 2009;179:220-227.
3. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008;133:1120-1127. (Pubitemid 351685515)
4. Luecke T, Muench E, Roth H, Friess U, Paul T, Kleinhuber K, Quintel M. Predictors of mortality in ARDS patients referred to a tertiary care centre: a pilot study. Eur J Anaesthesiol 2006;23:403-410.
5. Shann F. Mortality prediction model is preferable to APACHE. BMJ 2000;320:714. (Pubitemid 30179405)
6. Polderman K, Christiaans H, Wester J, Spijkstra J, Girbes A. Intraobserver variability in APACHE II scoring. Intensive Care Med 2001;27:1550-1552.
7. Kruse JA, Thill-Baharozian MC, Carlson RW. Comparison of clinical assessment with APACHE II for predicting mortality risk in patients admitted to a medical intensive care unit. JAMA 1988;260:1739-1742.
8. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F II, Park DR, Pugin J, Skerrett SJ, Hudson LD, Martin TR. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001;164:1896-1903. (Pubitemid 33152327)
9. Bauer TT, Monton C, Torres A, Cabello H, Fillela X, Maldonado A, Nicolas J-M, Zavala E. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 2000;55:46-52. (Pubitemid 30248778)
10. Wang Z, Beach D, Su L, Zhai R, Christiani DC. A genome-wide expression analysis in blood identifies pre-Elafin (PI3) as a biomarker in ARDS. Am J Respir Cell Mol Biol 2008;38:724-732. (Pubitemid 351841574)
11. Lorenz E, Muhlebach MS, Tessier PA, Alexis NE, Duncan Hite R, Seeds MC, Peden DB, Meredith W. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008;102:567-573.
12. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, Pesenti A. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008;36:2302-2308.
13. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703. (Pubitemid 29003951)
14. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999;274:13733-13736. (Pubitemid 129518665)
15. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, et al. TL1Ais a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002;16:479-492. (Pubitemid 34260924)
16. Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, Lin CH, Hsieh SL. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004;75:486-494. (Pubitemid 38316380)
17. You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, Hsieh SL. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008;111:1480-1488.
18. Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, Hsieh SL. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002;168:4846-4853. (Pubitemid 34495945)
19. Hsu MJ, Lin WW, Tsao WC, Chang YC, Hsu TL, Chiu AW, Chio CC, Hsieh SL. Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res 2004;292:241-251.
20. Wu SF, Liu TM, Lin YC, Sytwu HK, Juan HF, Chen ST, Shen KL, Hsi SC, Hsieh SL. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol 2004;75:293-306.
21. Shi G, Wu Y, Zhang J, Wu J. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol 2003;171:3407-3414. (Pubitemid 37254541)
22. Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y, Hyodoh F, Ueki H, Kusaka M, Kita S, et al. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol 2000;119:323-327. (Pubitemid 30073037)
23. Han B, Bojalil R, Amezcua-Guerra LM, Springall R, Valderrama-Carvajal H, Wu J, Luo H. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus. Int Immunol 2008;20:1067-1075.
24. Kim S, McAuliffe WJ, Zaritskaya LS, Moore PA, Zhang L, Nardelli B. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 2004;72:89-93. (Pubitemid 38018165)
25. Hsieh SL. Response: decoy receptor 3 (DcR3), a pleiotropic immunomodulator. Blood 2008;112:916.
26. Chen C, Yang K, Chen M, Chen H, Lee Y, Perng R, Hsieh S, Yang P, Chou T. High decoy receptor 3 levels in peripheral blood predict mortality in patients with acute respiratory distress syndrome [abstract]. Am J Respir Crit Care Med 2009;179:A5101.
27. Yang KY, Arcaroli JJ, Abraham E. Early alterations in neutrophil activation are associated with outcome in acute lung injury. Am J Respir Crit Care Med 2003;167:1567-1574. (Pubitemid 37363369)
28. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
29. Brun-Buisson C, Minelli C, Bertolini G, Brazzi L, Pimentel J, Lewandowski K, Bion J, Romand JA, Villar J, Thorsteinsson A, et al. Epidemiology and outcome of acute lung injury in European intensive care units. Results from the ALIVE study. Intensive Care Med 2004;30:51-61.
30. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. Ann Surg 1985;202:685-693.
31. Gibot S, Cravoisy A, Levy B, Bene M-C, Faure G, Bollaert P-E. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004;350:451-458. (Pubitemid 38133765)
32. Majetschak M, Krehmeier U, Bardenheuer M, Denz C, Quintel M, Voggenreiter G, Obertacke U. Extracellular ubiquitin inhibits the TNF-alpha response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood 2003;101:1882-1890. (Pubitemid 36237589)
33. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107:1062-1073.
34. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873. (Pubitemid 38344143)
35. Chen J, Zhang L, Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 2004;285:63-70. (Pubitemid 38186586)
36. Wortinger MA, Foley JW, Larocque P, Witcher DR, Lahn M, Jakubowski JA, Glasebrook A, Song HY. Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. Immunology 2003;110:225-233. (Pubitemid 37249262)
37. Matute-Bello G, Liles WC, Frevert CW, Dhanireddy S, Ballman K, Wong V, Green RR, Song HY, Witcher DR, Jakubowski JA, et al. Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen. J Infect Dis 2005;191:596-606. (Pubitemid 40216676)
38. Bellingan GJ. The pulmonary physician in critical care * 6: the pathogenesis of ALI/ARDS. Thorax 2002;57:540-546.
39. Martin TR. Cytokines and lung injury: searching for useful biomarkers. Crit Care Med 2005;33:230-232.
40. McClintock D, Zhuo H, Wickersham N, Matthay MA, Ware LB. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008;12:R41.
41. Ward NS, Casserly B, Ayala A. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med 2008;29:617-625. (viii.).
42. Geiser T, Atabai K, Jarreau PH, Ware LB, Pugin J, Matthay MA. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1beta-dependent mechanism. Am J Respir Crit Care Med 2001;163:1384-1388. (Pubitemid 32506603)
43. Parsons PE, Moss M, Vannice JL, Moore EE, Moore FA, Repine JE. Circulating IL-1ra and IL-10 levels are increased but do not predict the development of acute respiratory distress syndrome in at-risk patients. Am J Respir Crit Care Med 1997;155:1469-1473. (Pubitemid 27172800)
44. Yang CR, Hsieh SL, Ho FM, Lin WW. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 2005;174:1647-1656.
45. Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G, Gdynia G, Li L, Gretz N, Macher-Goeppinger S, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009;58:483-491.
46. Chen CC, Yang YH, Lin YT, Hsieh SL, Chiang BL. Soluble decoy receptor 3: increased levels in atopic patients. J Allergy Clin Immunol 2004;114:195-197.
47. Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol 2005;115:286-294. (Pubitemid 40712324)
48. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-430. (Pubitemid 37328939)